Zealand Deals Diabetes Drug to Aventis

Denmark's Zealand Pharma inked its second Big Pharma deal in as many months when it out-licensed its lead product, a Phase II diabetes treatment, to Aventis. Zealand's accelerated development of the product--which was tested immediately in patients, bypassing healthy volunteers--provided the firm with clinical proof of prinicple, on a budget.